GenMark Diagnostics (GenMark Diagnostics) Cash, Cash Equivalents, Marketable Securities : $128.2 Mil (As of Dec. 2020)

View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Cash, Cash Equivalents, Marketable Securities?

GenMark Diagnostics's quarterly cash, cash equivalents, marketable securities increased from Jun. 2020 ($132.80 Mil) to Sep. 2020 ($137.28 Mil) but then stayed the same from Sep. 2020 ($137.28 Mil) to Dec. 2020 ($128.15 Mil).

GenMark Diagnostics's annual cash, cash equivalents, marketable securities increased from Dec. 2018 ($45.17 Mil) to Dec. 2019 ($53.46 Mil) and increased from Dec. 2019 ($53.46 Mil) to Dec. 2020 ($128.15 Mil).

GenMark Diagnostics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for GenMark Diagnostics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GenMark Diagnostics Cash, Cash Equivalents, Marketable Securities Chart

GenMark Diagnostics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

41.57

71.99

45.17

53.46

128.15

GenMark Diagnostics Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															53.46	47.07	132.80	137.28	128.15

GenMark Diagnostics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

GenMark Diagnostics (NAS:GNMK) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

GenMark Diagnostics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

GenMark Diagnostics (GenMark Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5964 La Place Court, Carlsbad, CA, USA, 92008-8829

Website

http://www.genmarkdx.com

GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.

Executives

Tyler Jensen	officer: SVP, Engineering and Tech Dev	5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw	officer: VP, Assay Development	5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo	officer: VP, Qual, Reg, & Clin Affairs	5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson	officer: SVP, Corp. Accounts	5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler	officer: VP, Human Resources	5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins	officer: SVP, Sales	5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek	officer: Chief Financial Officer	5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel	director, officer: President & CEO	5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier	officer: SVP & General Counsel	5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell	officer: SVP, Operations	5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff	director	DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle	director	5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox	director	5964 LA PLACE COURT, CARLSBAD CA 92008